for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biocon Ltd

BION.NS

Latest Trade

408.20INR

Change

-5.60(-1.35%)

Volume

4,342,334

Today's Range

407.20

 - 

418.80

52 Week Range

211.05

 - 

446.95

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
413.80
Open
415.00
Volume
4,342,334
3M AVG Volume
168.50
Today's High
418.80
Today's Low
407.20
52 Week High
446.95
52 Week Low
211.05
Shares Out (MIL)
1,186.38
Market Cap (MIL)
488,670.10
Forward P/E
44.46
Dividend (Yield %)
0.12

Next Event

Half Year 2021 Biocon Ltd Earnings Release

Latest Developments

More

Biocon Biologics Announces Global Collaboration Agreement Between Unit & Voluntis

Equillium Says Planning Global Randomized Controlled Clinical Trial Of Itolizumab In COVID-19 Patients Under A U.S. IND

India's Biocon Says Itolizumab Receives DGCI Approval For Use In Moderate To Severe COVID-19 Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biocon Ltd

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Industry

Biotechnology & Drugs

Contact Info

20th KM, Hosur Road, Electronics City

560100

India

+91.80.28082808

http://www.biocon.com/

Executive Leadership

Kiran Mazumdar Mazumdar-Shaw

Executive Chairperson of the Board

Siddharth Mittal

Chief Executive Officer, Managing Director, Executive Director

John Mccallum Marshall Shaw

Non-Executive Vice Chairman of the Board

Indranil Sen

Interim Chief Financial Officer, Head of Finance, IR Contact Officer

Christiane Hamacher

Chief Executive Officer and Managing Director - Biocon Biologics

Key Stats

2.67 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

41.3K

2019

55.1K

2020

63.7K

2021(E)

79.9K
EPS (INR)

2018

3.135

2019

5.965

2020

5.730

2021(E)

9.107
Price To Earnings (TTM)
68.42
Price To Sales (TTM)
7.50
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
34.16
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

India's Biocon secures approval to use drug on coronavirus patients

India's Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday.

BRIEF-India's Biocon Says Itolizumab Receives DGCI Approval For Use In Moderate To Severe COVID-19 Patients

* SAYS DRUG ITOLIZUMAB RECEIVES DRUGS CONTROLLER GENERAL OF INDIA’S APPROVAL FOR ITS USE IN MODERATE TO SEVERE COVID-19 PATIENTS

BRIEF-Biocon Says Unit, DKSH Collaborate To Commercialize Seven Generic Formulations In South East Asia

* BIOCON LTD SAYS BIOCON PHARMA AND DKSH COLLABORATE TO COMMERCIALIZE SEVEN GENERIC FORMULATIONS IN SOUTH EAST ASIA MARKETS.

BRIEF-Biocon Unit Gets EU GMP Certification For Biosimilars Manufacturing Facilities In Bengaluru

* BIOCON BIOLOGICS RECEIVES EU GMP CERTIFICATION FOR MULTIPLE BIOSIMILARS MANUFACTURING FACILITIES IN BENGALURU Source text for Eikon: Further company coverage:

BRIEF-Biocon Biologics Drug Substance Facilities In Bengaluru Get EU GMP Certification

* BIOCON BIOLOGICS DRUG SUBSTANCE FACILITIES IN BENGALURU RECEIVE EU GMP CERTIFICATION Source text for Eikon: Further company coverage:

BRIEF-Biocon Gets FDA EIR For Bengaluru Small Molecules API Plant

* GETS ESTABLISHMENT INSPECTION REPORT FOR SMALL MOLECULES API MANUFACTURING FACILITY IN BENGALURU FOR PRE-APPROVAL & GMP U.S. FDA INSPECTION

BRIEF-Biocon Says Co, Mylan Launch Fulphila, Biosimilar Pegfilgrastim In Canada

* BIOCON LTD SAYS BIOCON AND MYLAN LAUNCH FULPHILA, BIOSIMILAR PEGFILGRASTIM, IN CANADA Source text for Eikon: Further company coverage:

BRIEF-Biocon Says Unit Get EIR From U.S. FDA For Two Manufacturing Facilities

* RECEIVES EIR FROM U.S. FDA FOR TWO MANUFACTURING FACILITIES

BRIEF-Biocon, Mylan Launch Fulphila Biosimilar Pegfilgrastim In Australia

* BIOCON AND MYLAN LAUNCH FULPHILA , BIOSIMILAR PEGFILGRASTIM, IN AUSTRALIA Source text for Eikon: Further company coverage:

BRIEF-Biocon Ltd -Insulin Manufacturing Facility In Malaysia Gets EIR From U.S. FDA

* BIOCON LTD -BIOCON'S INSULIN MANUFACTURING FACILITY IN MALAYSIA RECEIVES EIR FROM U.S. FDA WITH VOLUNTARY ACTION INDICATED

BRIEF-Biocon Ltd -Anticipate Delayed Deliveries For Some Products Due To Partial Shutdown

* BIOCON LTD -BIOCON LTD. AND BIOCON BIOLOGICS HAVE ACTIVATED BUSINESS CONTINUITY PLANS ACROSS THEIR FUNCTIONS

BRIEF-Biocon, Mylan Win Patent Litigation Asserted By Sanofi

* WON U.S. COURT RULING THAT INVALIDATED A SANOFI PATENT ON THE INSULIN GLARGINE DEVICE Further company coverage:

BRIEF-Biocon Says FDA Accepts Biologics License Application For Mylan, Co's Proposed Biosimilar Bevacizumab For Review

* BIOCON LTD - U.S. FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) FOR MYLAN AND BIOCON''S PROPOSED BIOSIMILAR BEVACIZUMAB FOR REVIEW

BRIEF-Biocon Gets 2 Observations From U.S. FDA For API Facility

* SMALL MOLECULES API MANUFACTURING FACILITY COMPLETES POST -APPROVAL AND GMP U.S. FDA INSPECTION

India's Biocon quarterly profit more than doubles, beats estimate

Indian biotechnology firm Biocon Ltd's quarterly profit more than doubled, handily beating analysts' estimates, largely driven by strong performance of its biologics businesses.

CORRECTED-India's Biocon Q2 profit surges on one-off gain

Indian biotechnology company Biocon Ltd posted an over five-fold rise in second-quarter profit on Thursday, as the company recorded a one-off gain of 1.89 billion rupees ($25.79 million).

CORRECTED-India's Biocon June-qtr profit jumps 47 pct, beats estimates

India's Biocon Ltd reported a 47 percent rise in June-quarter profit on Thursday, helped by higher income from its biologics and research services businesses.

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

India's Biocon Q4 profit rises 2.2 pct

Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up